Share

September 2020; 7 (5) ArticleOpen Access

Genetic determinants of the humoral immune response in MS

Christiane Gasperi, Till F.M. Andlauer, Ana Keating, Benjamin Knier, Ana Klein, Verena Pernpeintner, Peter Lichtner, Ralf Gold, Frauke Zipp, Florian Then Bergh, Martin Stangel, Hayrettin Tumani, Brigitte Wildemann, Heinz Wiendl, Antonios Bayas, Tania Kümpfel, Uwe K. Zettl, Ralf A. Linker, Ulf Ziemann, Matthias Knop, Clemens Warnke, Manuel A. Friese, Friedemann Paul, Björn Tackenberg, Achim Berthele, Bernhard Hemmer
First published July 16, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000827
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
450

Share

Article Information

vol. 7 no. 5 e827
DOI: 
https://doi.org/10.1212/NXI.0000000000000827
PubMed: 
32675288
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 28, 2020
  • Accepted in final form May 26, 2020
  • First Published July 16, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Christiane Gasperi, MD,
    2. Till F.M. Andlauer, PhD,
    3. Ana Keating, MSc,
    4. Benjamin Knier, MD,
    5. Ana Klein, MD,
    6. Verena Pernpeintner, MD,
    7. Peter Lichtner, PhD,
    8. Ralf Gold, MD,
    9. Frauke Zipp, MD,
    10. Florian Then Bergh, MD,
    11. Martin Stangel, MD,
    12. Hayrettin Tumani, MD,
    13. Brigitte Wildemann, MD,
    14. Heinz Wiendl, MD,
    15. Antonios Bayas, MD,
    16. Tania Kümpfel, MD,
    17. Uwe K. Zettl, MD,
    18. Ralf A. Linker, MD,
    19. Ulf Ziemann, MD,
    20. Matthias Knop, MD,
    21. Clemens Warnke, MD,
    22. Manuel A. Friese, MD,
    23. Friedemann Paul, MD,
    24. Björn Tackenberg, MD,
    25. Achim Berthele, MD and
    26. Bernhard Hemmer, MD
  1. Christiane Gasperi, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Deutsche Forschungsgemeinschaft (DFG) - 6-month research fellowship (grant number GA 2913/1-1)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Till F.M. Andlauer, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. My salary was paid by the Max Planck Institute of Psychiatry and, subsequently, the Klinikum rechts der Isar, using third party funding by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent, under the auspices of the e:Med Programme (grant 01ZX1614J) and through the DIFUTURE consortium of the Medical Informatics Initiative Germany (grant 01ZZ1804A), and by the European Union’s Horizon 2020 Research and Innovation Programme (grant MultipleMS, EU RIA 733161). None of these grants were awarded directly to me.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ana Keating, MSc,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Benjamin Knier, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer, Travel Compensation (2) Merck Serono, Travel Compensation (3) ECTRIMS (non-profit), travel grant (4) Neurowind e.V. (non-profit), travel grant (5) Novartis, Travel Compensation

    Editorial Boards:

    1. Frontiers in Neurology, Review Editor, 2020

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Kompetenznetz Multiple Sklerose (KKNMS), research grant from the Bundesministerium für Bildung und Forschung

    Research Support, Academic Entities:

    1. Kommission für Klinische Foschung (KKF), intramural research grant within the Technical University of Munich

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Ana Klein, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Verena Pernpeintner, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Peter Lichtner, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Ralf Gold, MD,
    9. Scientific Advisory Boards:

    1. (1) TEVA Laquinimod DSMB AbbVie

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis

    Editorial Boards:

    1. SAGE Journal TAND, Experimental Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. From Roche From Merck From Bayer

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Frauke Zipp, MD,
    10. Scientific Advisory Boards:

    1. (1) MPG (2) Merck Serono (3) Roche Novartis (4) Sanofi-Aventis (5) Celgene (6) ONO (7) Octapharma

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) MPG (2) Merck Serono (3) Roche Novartis (4) Sanofi-Aventis (5) Celgene (6) ONO (7) Octapharma

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme

    Research Support, Government Entities:

    1. (1) DFG CRC-TRR 128, Co-Spokesperson/Spokesperson, 2012-2020 (2) DFG CRC1080, PI, 2013-2020 (3) BMBF KKNMS, PI, 2013-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Progressive MS Alliance, BRAVEinMS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Florian Then Bergh, MD,
    11. Scientific Advisory Boards:

    1. Speaker honoraria and consultancy fees as a speaker and advisor from Actelion, Bayer Healthcare, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Support to attend scientific meetings from Bayer Schering, Biogen, Merck, Novartis and Sanofi-Genzyme

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Support for investigator-initiated trials from Actelion, Novartis. Travel support to attend scientific meetings, through the employing institution, from Bayer Schering, Biogen, Merck, Novartis and Sanofi Genzyme.

    Research Support, Government Entities:

    1. German Federal Ministry of Research; Deutsche Forschungsgemeinschaft (DFG, federal research funding agency)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Martin Stangel, MD,
    12. Scientific Advisory Boards:

    1. Alexion, Biogen, Bayer Healthcare, Baxalta/Shire/Takeda, Celgene, CSL Behring, Grifols, Janssen, MedDay, Merck- Serono, Novartis, Roche, Sanofi-Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva

    Editorial Boards:

    1. PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Merck-Serono, Novartis, Sanofi-Genzyme

    Research Support, Government Entities:

    1. Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), EU FP7

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Volkswagenstiftung

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Hayrettin Tumani, MD,
    13. Scientific Advisory Boards:

    1. Biogen Idec, Siemens Health, Teva Pharma, Roche, Merck.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Merck-Serono, AAN participation, 2009 TEVA, ECTRIMS participation, 2008 Biogen, ENS participation, 2009, 2010 TEVA, ENS participation, 2011 Novartis, INS participation 2013 Merck Serono, ECTRIMS participation 2013 Novartis,ENS participation 2014

    Editorial Boards:

    1. Neurology, Psychiatry and Brain Research (section editor) since 2011

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Several industries (Merck-Serono, Bayer, TEVA, Biogen) educational presentations, 2018-2000

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Merck, Teva, Novartis, Sanofi Genzyme, Siemens Health, Biogen, Roche Diagnostics.

    Research Support, Government Entities:

    1. BMBF (KKNMS-Project) 2015-2017 DMSG 2018-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Brigitte Wildemann, MD,
    14. Scientific Advisory Boards:

    1. Brigitte Wildemann served on scientific advisory boards for Novartis, Sanofi Genzyme, Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Brigitte Wildemann has received personal fees from Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, and Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Brigitte Wildemann reports grants from Deutsche Forschungsgemeinschaft, Bundesministerium für Forschung und Technologie, grants from Dietmar Hopp Stiftung, grants from Klaus Tschira Stiftung, grants from Merck Serono, Novartis Pharmaceuticals, and from Sanofi Genzyme

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Heinz Wiendl, MD,
    15. Scientific Advisory Boards:

    1. (1) Biogen, (2) Evgen (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Genzyme

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global

    Editorial Boards:

    1. (1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Abbvie (2) Actelion (3) Argenx (4) Biogen (5) EMD (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society (10)UCB

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi – Genzyme (7) Sanofi US (8) TEVA Pharma

    Research Support, Government Entities:

    1. (1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children’s Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Antonios Bayas, MD,
    16. Scientific Advisory Boards:

    1. (1) Merck Serono (2) Biogen (3) Novartis (4) TEVA (5) Sanofi/Genzyme (6) Roche (7) Alexion (8) Celgene (9) Bayer Vital

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Merck Serono: travel, speaker honoraria (2) Biogen: travel, speaker honoraria (3) Novartis: travel, speaker honoraria (4) TEVA: travel, speaker honoraria (5) Sanofi/Genzyme: travel, speaker honoraria (6) Roche: speaker honoraria (7) Alexion: speaker honoraria (8) Celgene: travel, speaker honoraria (9) Bayer Vital: speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck Serono (2) Biogen (3) Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Tania Kümpfel, MD,
    17. Scientific Advisory Boards:

    1. T. Kümpfel has served on advisory boards for Roche Pharma

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. T. Kümpfel has received speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche Pharma and Biogen as well as grant support from Novartis and Chugai Pharma in the past.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Uwe K. Zettl, MD,
    18. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel compensation for research meetings: (1) Aventis (2) Bayer (3) Biogen (4) Celgene Speakers fee: (1) Almirall (2) Alexion (3) Bayer (4) Biogen (5) Merck (6) Novartis (7) Roche (8) Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Ralf A. Linker, MD,
    19. Scientific Advisory Boards:

    1. Biogen, Celgene, Genzyme, Merck,Novartis, Roche.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen, Celgene, Genzyme, Merck, Novartis, Roche.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen, Novartis, Roche.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Ulf Ziemann, MD,
    20. Scientific Advisory Boards:

    1. (1) CorTec GmbH

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Vital GmbH, speaker honorarium (2) Biogen Idec GmbH, speaker honorarium (3) Bristol Myers Squibb GmbH, speaker honorarium (4) Medtronic GmbH, speaker honorarium (5) Pfizer Pharma GmbH, speaker honorarium

    Editorial Boards:

    1. (1) Clinical Neurophysiology, Editor-in-Chief, 4 years (2) Journal of Neuroscience, Associate Editor, 5 years (3) Brain Stimulation, Deputy Editor, 12 years (4) Experimental Brain Research, Editorial advisory board member, 15 years

    Patents:

    1. NONE

    Publishing Royalties:

    1. (1) Lehrbuch Neurologie (2nd edition), Elsevier, 2016 (2) Das TMS Buch, Springer, 2007 (3) The Oxford Handbook of Trancranial Stimulation, Oxford University Press, 2007

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Biogen Idec GmbH, Investigator initiated trial (2) Janssen Pharmaceuticals NV, Investigator initiated trial (3) Servier, Investigator initiated trial

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Matthias Knop, MD,
    21. Scientific Advisory Boards:

    1. (1) Biogen (2) Genzyme (3) Roche (4) Merck

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Clemens Warnke, MD,
    22. Scientific Advisory Boards:

    1. Biogen, Novartis, Roche; institutional fees only.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speakers honoraria Novartis, Biogen, Bayer, Genzyme, Alexion. Institutional fees only.

    Editorial Boards:

    1. Frontiers in Neurology, associate editor, 2016-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Speakers honoraria payed to the institution: Novartis, Biogen, Roche.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Manuel A. Friese, MD,
    23. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. MAF received honoraria for consultation and travel expenses from Biogen, Merck KGaA, Novartis and Roche unrelated to this work.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. German Research Foundation, German Ministry of Education and Research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  23. Friedemann Paul, MD,
    24. Scientific Advisory Boards:

    1. Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene

    Editorial Boards:

    1. Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono

    Research Support, Government Entities:

    1. German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  24. Björn Tackenberg, MD,
    25. Scientific Advisory Boards:

    1. Commercial(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Commercial, speaker honoraria(1) CSL Behring(2) Grifols(3) Octapharma(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. F. Hoffmann-La Roche AG, Basel, Switzerland

    Consultancies:

    1. Commercial, Consultancy fees(1) CSL Behring(2) Grifols(3) Biogen(4) Novartis(5) Bayer Healthcare(6) Genzyme(7) UCB(8) Roche(9) GILEAD

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial(1) Biogen(2) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. F. Hofmann-La Roche AG Basel

    Legal Proceedings:

    1. NONE

  25. Achim Berthele, MD and
    26. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I received funding for travel and speaker honoraria from Alexion, Bayer Healthcare, Biogen, Genzyme, Merck Serono, Mylan,Novartis, Roche and Teva.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have received consultancies from Alexion, Bayer Healthcare, Biogen, Celgene and Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  26. Bernhard Hemmer, MD
    27. Scientific Advisory Boards:

    1. Advisory Boards for Novartis, he has served as DMSC member for AllergyCare, TG Therapeutics and Polpharma Biologics

    Gifts:

    1. Me or my institution have received speaker honoraria from Desitin

    Funding for travel or speaker honoraria:

    1. Excemed

    Editorial Boards:

    1. Editorial board member of Jama Neurology, Experimental Neurology and Multiple sclerosis Journal

    Patents:

    1. I hold part of two patents; one for the detection of antibodies and T cells against KIR4.1 in a subpopulati on of MS patients and one for genetic determinants of neutralizing antibodies to interferon β

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. German Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium für Bildung und Forschung

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (C.G., T.F.M.A., A. Keating, B.K., A. Klein, V.P., A. Berthele, B.H.), Klinikum rechts der Isar, School of Medicine, Technical University of Munich; Institute of Human Genetics (P.L.), Helmholtz Zentrum München, Neuherberg; Department of Neurology (R.G.), St. Josef Hospital, Ruhr-University Bochum; Department of Neurology, Focus Program Translational Neurosciences (FTN) and Research Center for Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2) (F.Z.), University Medical Center of the Johannes Gutenberg University Mainz; Department of Neurology and Translational Center for Regenerative Medicine (F.T.B.), University of Leipzig; Clinical Neuroimmunology and Neurochemistry (M.S.), Department of Neurology, Hannover Medical School, Hannover; Department of Neurology (H.T.), University of Ulm; Clinic of Neurology Dietenbronn (H.T.), Schwendi; Department of Neurology (B.W.), University Hospital Heidelberg; Department of Neurology (H.W.), University of Münster; Department of Neurology (A. Bayas), University Hospital Augsburg; Institute of Clinical Neuroimmunology (T.K.), University Hospital and Biomedical Center, Ludwig-Maximilians University Munich; Department of Neurology (U.K.Z.), Neuroimmunological Section, University of Rostock; Department of Neurology (R.A.L.), University Hospital Erlangen; Department of Neurology (R.A.L.), University of Regensburg; Department of Neurology & Stroke and Hertie-Institute for Clinical Brain Research (U.Z.), Eberhard-Karls-Universität Tübingen; Max Planck Institute of Psychiatry (M.K.), Munich; Department of Neurology (C.W.), Medical Faculty, Heinrich Heine University, Düsseldorf; Department of Neurology (C.W.), University Hospital Cologne; Institute of Neuroimmunology and Multiple Sclerosis (M.A.F), University Medical Centre Hamburg-Eppendorf, Hamburg; NeuroCure Clinical Research Center (F.P.), Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin Institute of Health and Experimental and Clinical Research Center (F.P.), Max Delbrück Center for Molecular Medicine and Charité—Universitätsmedizin Berlin; and Center of Neuroimmunology (B.T.), Philipps-University Marburg; and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany.
  1. Correspondence
    Dr. Hemmer hemmer{at}tum.de
View Full Text

Article usage

Article usage: July 2020 to February 2021

AbstractFullPdfSource
Jul 202019484102Highwire
Aug 2020718457Highwire
Sep 202091208103Highwire
Oct 2020630687Highwire
Nov 202076023Highwire
Dec 202054919Highwire
Jan 202165528Highwire
Feb 202115631Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Advertisement